Patient characteristics
| Median age | 41 (range, 12-63) |
| Diagnosis | |
| Chronic myeloid leukemia | 55 (52%) |
| Acute myeloid leukemia | 19 (18%) |
| Acute lymphoid leukemia | 9 (9%) |
| Acute biphenotypic leukemia | 1 (1%) |
| Myelodysplasia | 12 (11%) |
| Myelofibrosis | 2 (2%) |
| Essential thrombocythemia | 1 (1%) |
| Multiple myeloma | 2 (2%) |
| Non-Hodgkin lymphoma | 3 (3%) |
| Hodgkin disease | 1 (1%) |
| Donor compatibility | |
| HLA-identical siblings | 54 (51%) |
| HLA-A–, -B– and -DR–matched unrelated volunteers | 38 (36%) |
| HLA-mismatched relatives | 6 (6%) |
| HLA-mismatched unrelated volunteers | 7 (7%) |
| Pretransplant splenectomy | 3 (3%) |
| Number of previous hematopoietic cell transplants | |
| 0 | 100 (95%) |
| 1 | 5 (5%) |
| Conditioning* | |
| Busulfan + cyclophosphamide | 42 (40%) |
| Total body irradiation + cyclophosphamide | 54 (52%) |
| Other | 9 (9%) |
| Graft | |
| T-cell replete marrow | 105 (100%) |
| GVHD prophylaxis | |
| Cyclosporine (daily until d 180) + methotrexate (d 1, 3, 6, 11) | 92 (88%) |
| Other | 13 (12%) |
| Graft failure | 0 (0%) |
| Acute GVHD grade† | |
| 0 | 10 (10%) |
| 1 | 4 (4%) |
| 2 | 77 (73%) |
| 3 | 14 (13%) |
| 4 | 0 (0%) |
| Chimerism status on day 80 | |
| Full (more than 90% marrow cells of donor origin) | 104 (99%) |
| Mixed (88% marrow cells of donor origin) | 1 (1%) |
| Relapse before day 365 | 8 (8%) |
| Nonrelapse death before day 365 | 11 (10%) |
| Clinical extensive chronic GVHD diagnosed before day 365‡ | 64 (61%) |
| Median age | 41 (range, 12-63) |
| Diagnosis | |
| Chronic myeloid leukemia | 55 (52%) |
| Acute myeloid leukemia | 19 (18%) |
| Acute lymphoid leukemia | 9 (9%) |
| Acute biphenotypic leukemia | 1 (1%) |
| Myelodysplasia | 12 (11%) |
| Myelofibrosis | 2 (2%) |
| Essential thrombocythemia | 1 (1%) |
| Multiple myeloma | 2 (2%) |
| Non-Hodgkin lymphoma | 3 (3%) |
| Hodgkin disease | 1 (1%) |
| Donor compatibility | |
| HLA-identical siblings | 54 (51%) |
| HLA-A–, -B– and -DR–matched unrelated volunteers | 38 (36%) |
| HLA-mismatched relatives | 6 (6%) |
| HLA-mismatched unrelated volunteers | 7 (7%) |
| Pretransplant splenectomy | 3 (3%) |
| Number of previous hematopoietic cell transplants | |
| 0 | 100 (95%) |
| 1 | 5 (5%) |
| Conditioning* | |
| Busulfan + cyclophosphamide | 42 (40%) |
| Total body irradiation + cyclophosphamide | 54 (52%) |
| Other | 9 (9%) |
| Graft | |
| T-cell replete marrow | 105 (100%) |
| GVHD prophylaxis | |
| Cyclosporine (daily until d 180) + methotrexate (d 1, 3, 6, 11) | 92 (88%) |
| Other | 13 (12%) |
| Graft failure | 0 (0%) |
| Acute GVHD grade† | |
| 0 | 10 (10%) |
| 1 | 4 (4%) |
| 2 | 77 (73%) |
| 3 | 14 (13%) |
| 4 | 0 (0%) |
| Chimerism status on day 80 | |
| Full (more than 90% marrow cells of donor origin) | 104 (99%) |
| Mixed (88% marrow cells of donor origin) | 1 (1%) |
| Relapse before day 365 | 8 (8%) |
| Nonrelapse death before day 365 | 11 (10%) |
| Clinical extensive chronic GVHD diagnosed before day 365‡ | 64 (61%) |
HLA indicates human lymphocyte antigens; GVHD, graft-versus-host disease.
Usual dosing: busulfan, 16 mg/kg, cyclophosphamide, 120 mg/kg, total body irradiation, 12.0-13.2 Gy.
Treated usually with prednisone 2 mg/kg for 10 to 14 days with subsequent taper over 50 days.
Treated usually with prednisone (0.5-1.0 mg/kg every other day plus cyclosporine (approximately 6 mg/kg orally every other day) for at least 9 months.